Drinking water source and human Toxoplasma gondii infection in the United States: a cross-sectional analysis of NHANES data

BMC Public Health

Timothy J Wade¹  Reagan R Converse¹  Elizabeth D Hilborn¹  Whitney S Krueger¹ 

[1] Environmental Public Health Division, Office of Research and Development, US Environmental Protection Agency, 104 Mason Farm Road, Chapel Hill, North Carolina, USA

关键词: Cross-sectional studies;    Water wells;    Drinking water;    Toxoplasma;    Nutrition surveys;   

Others  :  866277
DOI  :  10.1186/1471-2458-14-711

 received in 2014-03-11, accepted in 2014-07-03,  发布年份 2014

【 摘 要 】

Background

Toxoplasma gondii imparts a considerable burden to public health. Human toxoplasmosis can be life-threatening in immunocompromised individuals, has been associated with psychiatric disorders, and can cause severe congenital pathologies, spontaneous abortion, or stillbirth. Environmental modes of transmission contributing to the incidence of human toxoplasmosis are poorly understood. We sought to examine National Health and Nutrition Examination Survey (NHANES) data for risk factors associated with T. gondii seroprevalence.

Methods

T. gondii serology results reported for Continuous NHANES survey years 1999–2004 and 2009–10 were examined. To explore associations with toxoplasmosis seropositivity, covariates of interest were selected a priori, including source and home treatment of tap water. Associations between potential risk factors and evidence of IgG antibodies against T. gondii were assessed using multivariable logistic regression.

Results

Among 23,030 participants with available T. gondii serology across 8 years of continuous NHANES survey data (1999–2004; 2009–2010), persons born outside the United States were significantly more likely to be seropositive, and seropositivity was inversely associated with years spent in the United States. Among US-born participants, participants with homes on well water (both those who used at-home water treatment devices and those who did not), as well as participants with public/private company-provided tap water who did not use at-home water treatment devices, were significantly more likely to be seropositive compared to participants who used home treatment devices on tap water provided by a private or public water company. A comparative subpopulation analysis revealed age-adjusted seroprevalence among US-born persons 12-49 yrs old significantly declined to 6.6% (95% CI, 5.2-8.0) (P <0.0001) in 2009–10, compared to previously published reports for NHANES data from 1988–1994 (14.1%) and 1999–2004 (9.0%).

Conclusions

Data suggests that T. gondii infections continue to decline in the United States, but the overall infection rate remains substantial at nearly 7%. Despite the limitations in the Continuous NHANES cross-sectional survey, the association between well water use and T. gondii infection warrants further research.

【 授权许可】

   
2014 Krueger et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Robert-Gangneux F, Darde ML: Epidemiology of and diagnostic strategies for toxoplasmosis. Clinical Microbiology Reviews 2012, 25(2):264-296.
• [2]Nelson KE, Williams CM: Infectious disease epidemiology. Third edition Burlington, MA: Jones & Bartlett Learning; 2014.
• [3]National Center for Health Statistics: National health and nutrition examination survey data. Hyattsville, MD: U.S. Department of Health and Human Services Centers for Disease Control and Prevention; 2013.
• [4]Jones JL, Dubey JP: Waterborne toxoplasmosis–recent developments. Exp Parasitol 2010, 124(1):10-25.
• [5]Lass A, Pietkiewicz H, Modzelewska E, Dumetre A, Szostakowska B, Myjak P: Detection of Toxoplasma gondii oocysts in environmental soil samples using molecular methods. Eur J Clin Microbiol Infect Dis 2009, 28(6):599-605.
• [6]Hill D, Dubey JP: Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect 2002, 8(10):634-640.
• [7]Webster JP, Lamberton PH, Donnelly CA, Torrey EF: Parasites as causative agents of human affective disorders? the impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii’s ability to alter host behaviour. Proc Biol Sci 2006, 273(1589):1023-1030.
• [8]Shepp DH, Hackman RC, Conley FK, Anderson JB, Meyers JD: Toxoplasma gondii reactivation identified by detection of parasitemia in tissue culture. Ann Intern Med 1985, 103(2):218-221.
• [9]Montoya JG, Liesenfeld O: Toxoplasmosis. Lancet 2004, 363(9425):1965-1976.
• [10]Fekadu A, Shibre T, Cleare AJ: Toxoplasmosis as a cause for behaviour disorders–overview of evidence and mechanisms. Folia Parasitol (Praha) 2010, 57(2):105-113.
• [11]Pearce BD, Kruszon-Moran D, Jones JL: The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey. Biol Psychiatry 2012, 72(4):290-295.
• [12]Pappas G, Roussos N, Falagas ME: Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 2009, 39(12):1385-1394.
• [13]Collier SA, Stockman LJ, Hicks LA, Garrison LE, Zhou FJ, Beach MJ: Direct healthcare costs of selected diseases primarily or partially transmitted by water. Epidemiol and Infect 2012, 140(11):2003-2013.
• [14]Cook AJ, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA, Foulon W, Semprini AE, Dunn DT: Sources of Toxoplasma infection in pregnant women: European multicentre case–control study: European research network on congenital toxoplasmosis. BMJ 2000, 321(7254):142-147.
• [15]Boyer KM, Holfels E, Roizen N, Swisher C, Mack D, Remington J, Withers S, Meier P, McLeod R, Toxoplasmosis Study Group: Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening. Am J Obstet Gynecol 2005, 192(2):564-571.
• [16]Tenter AM, Heckeroth AR, Weiss LM: Toxoplasma gondii: from animals to humans. Int J Parasitol 2000, 30(12–13):1217-1258.
• [17]Dubey JP: Toxoplasma gondii oocyst survival under defined temperatures. J Parasitol 1998, 84(4):862-865.
• [18]Dumetre A, Le Bras C, Baffet M, Meneceur P, Dubey JP, Derouin F, Duguet JP, Joyeux M, Moulin L: Effects of ozone and ultraviolet radiation treatments on the infectivity of Toxoplasma gondii oocysts. Vet Parasitol 2008, 153(3–4):209-213.
• [19]Ware MW, Augustine SA, Erisman DO, See MJ, Wymer L, Hayes SL, Dubey JP, Villegas EN: Determining UV inactivation of Toxoplasma gondii oocysts by using cell culture and a mouse bioassay. Appl Environ Microbiol 2010, 76(15):5140-5147.
• [20]Benenson MW, Takafuji ET, Lemon SM, Greenup RL, Sulzer AJ: Oocyst-transmitted toxoplasmosis associated with ingestion of contaminated water. N Engl J Med 1982, 307(11):666-669.
• [21]Bowie WR, King AS, Werker DH, Isaac-Renton JL, Bell A, Eng SB, Marion SA: Outbreak of toxoplasmosis associated with municipal drinking water: the BC Toxoplasma investigation team. Lancet 1997, 350(9072):173-177.
• [22]Burnett AJ, Shortt SG, Isaac-Renton J, King A, Werker D, Bowie WR: Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology 1998, 105(6):1032-1037.
• [23]Dubey JP, Jones JL: Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol 2008, 38(11):1257-1278.
• [24]Torrey EF, Yolken RH: Toxoplasma oocysts as a public health problem. Trends Parasitol 2013, 29(8):380-384.
• [25]Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB: Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 2001, 154(4):357-365.
• [26]Jones JL, Kruszon-Moran D, Wilson M: Toxoplasma gondii infection in the United States, 1999–2000. Emerg Infect Dis 2003, 9(11):1371-1374.
• [27]Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M: Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. Am J Trop Med Hyg 2007, 77(3):405-410.
• [28]McQuillan GM, Kruszon-Moran D, Kottiri BJ, Curtin LR, Lucas JW, Kington RS: Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988–1994. Am J Public Health 2004, 94(11):1952-1958.
• [29]Betancourt WQ, Rose JB: Drinking water treatment processes for removal of cryptosporidium and giardia. Vet Parasitol 2004, 126(1–2):219-234.
• [30]Craun GF, Brunkard JM, Yoder JS, Roberts VA, Carpenter J, Wade T, Calderon RL, Roberts JM, Beach MJ, Roy SL: Causes of outbreaks associated with drinking water in the United States from 1971 to 2006. Clin Microbiol Rev 2010, 23(3):507-528.
• [31]Sroka J, Wojcik-Fatla A, Dutkiewicz J: Occurrence of Toxoplasma gondii in water from wells located on farms. Ann Agric Environ Med 2006, 13(1):169-175.
• [32]Dubey JP, Lindsay DS, Speer CA: Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 1998, 11(2):267-299.
• [33]MacLaren A, De Souza W: Further studies on the interaction of Toxoplasma gondii with neutrophils and eosinophils. J Submicrosc Cytol Pathol 2002, 34(1):99-104.
• [34]Johnson LL, Berggren KN, Szaba FM, Chen W, Smiley ST: Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med 2003, 197(6):801-806.
• [35]Michelson AD, Lammi AT: Haemolytic anaemia associated with acquired toxoplasmosis. Aust Paediatr J 1984, 20(4):333-335.
• [36]Neves ES, Bicudo LN, Curi AL, Carregal E, Bueno WF, Ferreira RG, Amendoeira MR, Benchimol E, Fernandes O: Acute acquired toxoplasmosis: clinical-laboratorial aspects and ophthalmologic evaluation in a cohort of immunocompetent patients. Mem Inst Oswaldo Cruz 2009, 104(2):393-396.
• [37]Nakazaki S, Saeki N, Itoh S, Osato K, Watanabe O, Hamada N, Mitsuhashi H, Shin H, Kiuchi I, Kobayashi C, Yano A, Yamaura A: Toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome–four case reports. Neurol Med Chir (Tokyo) 2000, 40(2):120-123.
• [38]Conrad PA, Miller MA, Kreuder C, James ER, Mazet J, Dabritz H, Jessup DA, Gulland F, Grigg ME: Transmission of Toxoplasma: clues from the study of sea otters as sentinels of Toxoplasma gondii flow into the marine environment. Int J Parasitol 2005, 35(11–12):1155-1168.
• [39]Hill D, Coss C, Dubey JP, Wroblewski K, Sautter M, Hosten T, Munoz-Zanzi C, Mui E, Withers S, Boyer K, Hermes G, Coyne J, Jagdis F, Burnett A, McLeod P, Morton H, Robinson D, McLeod R: Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol 2011, 97(2):328-337.